Inozyme Pharma Statistics
Total Valuation
Inozyme Pharma has a market cap or net worth of $172.81 million. The enterprise value is $94.41 million.
Important Dates
The last earnings date was Tuesday, November 5, 2024, before market open.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Inozyme Pharma has 64.24 million shares outstanding. The number of shares has increased by 31.49% in one year.
| Current Share Class | 64.24M |
| Shares Outstanding | 64.24M |
| Shares Change (YoY) | +31.49% |
| Shares Change (QoQ) | +2.15% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 51.63% |
| Float | 36.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.16 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.68, with a Debt / Equity ratio of 0.57.
| Current Ratio | 7.68 |
| Quick Ratio | 7.17 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.40 |
Financial Efficiency
Return on equity (ROE) is -79.42% and return on invested capital (ROIC) is -38.46%.
| Return on Equity (ROE) | -79.42% |
| Return on Assets (ROA) | -35.69% |
| Return on Capital (ROIC) | -38.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.64M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.03% in the last 52 weeks. The beta is 1.54, so Inozyme Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | -31.03% |
| 50-Day Moving Average | 4.73 |
| 200-Day Moving Average | 5.10 |
| Relative Strength Index (RSI) | 15.50 |
| Average Volume (20 Days) | 346,933 |
Short Selling Information
The latest short interest is 3.23 million, so 5.03% of the outstanding shares have been sold short.
| Short Interest | 3.23M |
| Short Previous Month | 3.21M |
| Short % of Shares Out | 5.03% |
| Short % of Float | 8.83% |
| Short Ratio (days to cover) | 14.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -99.67M |
| Pretax Income | -88.56M |
| Net Income | -96.49M |
| EBITDA | -98.89M |
| EBIT | -99.67M |
| Earnings Per Share (EPS) | -$1.55 |
Full Income StatementBalance Sheet
The company has $131.61 million in cash and $46.79 million in debt, giving a net cash position of $84.82 million or $1.32 per share.
| Cash & Cash Equivalents | 131.61M |
| Total Debt | 46.79M |
| Net Cash | 84.82M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 82.79M |
| Book Value Per Share | 1.29 |
| Working Capital | 122.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$91.21 million and capital expenditures -$150,000, giving a free cash flow of -$91.36 million.
| Operating Cash Flow | -91.21M |
| Capital Expenditures | -150,000 |
| Free Cash Flow | -91.36M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |